At the time of writing, EyePoint Pharmaceuticals Inc [EYPT] stock is trading at $27.68, down -3.45%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EYPT shares have gain 3.94% over the last week, with a monthly amount glided 3.63%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences. In a post published today on Yahoo Finance, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that Company management will participate at the following upcoming conferences:.
From an analyst’s perspective:
EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] stock has seen the most recent analyst activity on January 22, 2024, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $35. Previously, Mizuho started tracking the stock with Buy rating on November 02, 2023, and set its price target to $20. On April 21, 2023, Robert W. Baird initiated with a Outperform rating and assigned a price target of $33 on the stock. Chardan Capital Markets started tracking the stock assigning a Buy rating and suggested a price target of $21 on July 07, 2022. Cowen initiated its recommendation with a Outperform and recommended $25 as its price target on March 01, 2021. Cantor Fitzgerald started tracking with a Overweight rating for this stock on January 28, 2021, and assigned it a price target of $22. In a note dated April 06, 2020, B. Riley FBR downgraded an Neutral rating on this stock and revised its target price from $4 to $1.
For the past year, the stock price of EyePoint Pharmaceuticals Inc fluctuated between $2.21 and $30.99. Currently, Wall Street analysts expect the stock to reach $25 within the next 12 months. EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] shares were valued at $27.68 at the most recent close of the market. An investor can expect a potential drop of -9.68% based on the average EYPT price forecast.
Analyzing the EYPT fundamentals
According to EyePoint Pharmaceuticals Inc [NASDAQ:EYPT], the company’s sales were 42.52M for trailing twelve months, which represents an 51.84% jump. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -1.92%, Pretax Profit Margin comes in at -2.36%, and Net Profit Margin reading is -2.85%. To continue investigating profitability, this company’s Return on Assets is posted at -0.76, Equity is -1.67 and Total Capital is -0.85. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 26.97 points at the first support level, and at 26.26 for the second support level. However, for the 1st resistance point, the stock is sitting at 28.76, and for the 2nd resistance point, it is at 29.85.
EyePoint Pharmaceuticals Inc [EYPT] reported earnings per share of -$0.33 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.51/share, meaning a difference of $0.18 and a surprise factor of 35.30%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.61 per share as compared to estimates of $0.6 per share, a difference of -$1.21 representing a surprise of -201.70%.
Ratios To Look Out For
It is important to note that EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] has a current ratio of 2.35. Further, the Quick Ratio stands at 2.28, while the Cash Ratio is 2.08. Considering the valuation of this stock, the price to sales ratio is 31.79, the price to book ratio is 16.67.
Transactions by insiders
Recent insider trading involved Jones David Scott, SVP & Chief Commercial Officer, that happened on Feb 02 when 209.0 shares were sold. Chief Medical Officer, Paggiarino Dario A. completed a deal on Jan 26 to sell 49325.0 shares. Meanwhile, SVP & Chief Commercial Officer Jones David Scott sold 26017.0 shares on Jan 26.
